Herantis Pharma (OHEL:HRTIS) Interest Expense: €-0.33 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OHEL:HRTIS Herantis Pharma PLC OHEL:HRTIS
26 GF Score
Price €1.53
! 3 Warning Signs
View Full Analysis

What is Herantis Pharma Interest Expense?

Herantis Pharma OHEL:HRTIS +0.13% 26 Interest Expense is €-0.33 Mil as of Jun. 2026. GuruFocus rates OHEL:HRTIS with a GF Score™ of 26/100. The stock has 3 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Herantis Pharma's interest expense for the six months ended in Jun. 2026 was € -0.30 Mil. Its interest expense for the trailing twelve months (TTM) ended in Jun. 2026 was €-0.33 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Herantis Pharma's Operating Income for the six months ended in Jun. 2026 was € -3.06 Mil. Herantis Pharma's Interest Expense for the six months ended in Jun. 2026 was € -0.30 Mil. Herantis Pharma did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Herantis Pharma  (OHEL:HRTIS) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Herantis Pharma's Interest Expense for the six months ended in Jun. 2026 was €-0.30 Mil. Its Operating Income for the six months ended in Jun. 2026 was €-3.06 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Jun. 2026 was €0.02 Mil.

Herantis Pharma's Interest Coverage for the quarter that ended in Jun. 2026 is calculated as

Herantis Pharma did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Herantis Pharma Interest Expense Historical Data

* Premium members only.

The historical data trend for Herantis Pharma's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Herantis Pharma Interest Expense Chart

Herantis Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -14.53 -0.07 -0.02 0.00 -0.01

Herantis Pharma Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.00 -0.00 -0.33 -0.03 -0.30
OHEL:HRTIS
26GF Score
Herantis Pharma PLC OHEL:HRTIS
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Herantis Pharma Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.33 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of €-0.33 Mil mean?
Herantis Pharma (OHEL:HRTIS) has a Interest Expense of €-0.33 Mil as of Jun. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Herantis Pharma and its competitors.
Is Herantis Pharma's Interest Expense too high?
Herantis Pharma's current Interest Expense is €-0.33 Mil. Overall, Herantis Pharma has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Herantis Pharma's Interest Expense compare to VRTX and REGN?
Herantis Pharma's Interest Expense of €-0.33 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Herantis Pharma and its competitors. Herantis Pharma's current Interest Expense is €-0.33 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Herantis Pharma stock overvalued right now?
Herantis Pharma (OHEL:HRTIS) has a current Interest Expense of €-0.33 Mil. The current Interest Expense is €-0.33 Mil. Herantis Pharma's overall GF Score™ is 26/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Herantis Pharma (OHEL:HRTIS), the current Interest Expense is €-0.33 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Herantis Pharma Business Description

Address Bertel Jungin Aukio 1, Espoo, FIN, 02600
Herantis Pharma PLC is a biotech company developing disease-modifying therapies for Parkinsons disease. The company's current development program focuses solely on HER-096, which is a peptidomimetic molecule designed to retain the biological activity of the neuroprotective CDNF protein.
26GF Score

Get the complete analysis for OHEL:HRTIS

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.53
Price